England have been drawn into Group L alongside Croatia, Ghana and Panama at the 2026 World Cup - here's who they could face in the knockout stages England would only qualify for the Round of 32 if ...

Walking into medical school without a roadmap hits differently when you are the first in your family to do it. No insider language, no built-in mentors, no one who can explain the difference between ...

Exact agreed to be bought out by Abbott Labs for $105 per share. The buyout is at a hefty premium to the share price at the start of the week, but still well below Exact's 2021 highs. Shareholders ...

Abbott announced on Thursday, Nov. 20 it plans to buy Exact Sciences, a Madison-based maker of cancer screening and diagnostic tests, in a deal valued at an estimated $23 billion, including debt. The ...

Abbott to buy Exact Sciences in $23 billion deal Exact's flagship colorectal cancer test to join Abbott's portfolio Abbott eyes international expansion for Exact's tests Aims for broad reimbursement ...

Forbes contributors publish independent expert analyses and insights. Bruce Japsen writes about healthcare business and policy. Abbott Laboratories $21 billion deal to acquire cancer test maker Exact ...

Abbott Laboratories ABT0.26%increase; green up pointing triangle agreed to acquire cancer diagnostics company Exact Sciences EXAS 0.43%increase; green up pointing triangle in a deal valued at about ...

(RTTNews) - Abbott Laboratories (ABT) on Thursday said it has agreed to acquire Exact Sciences (EXAS) in a transaction worth an enterprise value of about $23 billion. Under the terms of the agreement, ...

Gift Article 10 Remaining As a subscriber, you have 10 articles to gift each month. Gifting allows recipients to access the article for free. Abbott Laboratories agreed to acquire cancer-screening ...

Investing.com -- Exact Sciences (NASDAQ:EXAS) stock soared 17% Thursday, building on Wednesday’s 24% surge after Abbott (NYSE:ABT) announced plans to acquire the cancer diagnostics company in a deal ...

(Reuters) -Abbott will buy cancer test maker Exact Sciences in a deal valued at up to $23 billion, including debt, marking one of its largest purchases in nearly a decade and a bold entry into the ...

The acquisition will allow the diagnostics giant to enter the rapidly growing market for cancer tests Exact Sciences sells Cologuard, the at-home test for colorectal cancer that allows some patients ...